Specimen and Data Study for Ovarian Cancer Early Detection and Prevention (NCT00005095) | Clinical Trial Compass
RecruitingNot Applicable
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
United States6,000 participantsStarted 2000-03
Plain-language summary
RATIONALE: To improve strategies for detection and prevention of early-stage disease.
PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.
Who can participate
Age range18 Years – 80 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Meets one of the following criteria:
* Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:
* Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer
* Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor
* A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer
* Increased risk as deemed by a certified genetic counselor
* Undergoing surgery for a gynecologic condition, including any of the following:
* Diagnosis of a reproductive cancer
* Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)
* Highly suspicious adnexal mass
* Risk-reducing prophylactic oophorectomy
PATIENT CHARACTERISTICS:
Age
* Between the ages of 18 and 80
What they're measuring
1
The development of ultrasound and serum tumor markers for the detection and management of ovarian cancer and other